A Pragmatic Approach to Psychedelic Drug Development
December 6, 2024
In this episode, Brandon Li sits down with Srinivas Rao, Co-CEO of atai Life Sciences, for a deep dive into the pragmatic strategies shaping the future of psychedelic therapies. Srini shares how his background in engineering and neuropharmacology has informed a streamlined, patient-centric approach to drug development.
Key topics include:
The evolution of atai Life Sciences, from a fund to a biotech company.
Innovative drug delivery approaches, like DMT oral thin films, and why simplicity and scalability matter.
Balancing diverse compounds and therapeutic areas with a focused portfolio strategy.
Advancing research in areas like social anxiety disorder and cognitive impairment in schizophrenia.
Tackling clinical trial challenges, including the placebo effect and trial design complexities.
Tune in to hear how a pragmatic lens is redefining what’s possible in neuropsychiatric drug development.
In this episode, Brandon Li sits down with Srinivas Rao, Co-CEO of atai Life Sciences, for a deep dive into the pragmatic strategies shaping the future of psychedelic therapies. Srini shares how his background in engineering and neuropharmacology has informed a streamlined, patient-centric approach to drug development.
Key topics include:
- The evolution of atai Life Sciences, from a fund to a biotech company.
- Innovative drug delivery approaches, like DMT oral thin films, and why simplicity and scalability matter.
- Balancing diverse compounds and therapeutic areas with a focused portfolio strategy.
- Advancing research in areas like social anxiety disorder and cognitive impairment in schizophrenia.
- Tackling clinical trial challenges, including the placebo effect and trial design complexities.
Tune in to hear how a pragmatic lens is redefining what’s possible in neuropsychiatric drug development.